— Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants — — Initial proof of concept data expected in second half of 2027 — SAN DIEGO, Oct. 27, 2026 /PRNewswire/ — Atrium Therapeutics, Inc. (Nasdaq: RNA) (the “Company”), a biopharmaceutical company advancing…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
